


CLAIMS

1. A compound of Formula (IV):



or a pharmaceutically acceptable salt thereof, wherein:

X¹ is -F, -Cl, -CF₃, -CN, or -CH₃;

X² is -H, -F, or -Cl;

Z¹ is N or CH;

Z² is N or CR⁰;

R⁰ is -H, -F, or -CN;


R¹, R², and R³ are each independently -CH₃, -CH₂F, -CF₃, -C₂H₅, -CH₂CH₂F, or -CH₂CF₃;

R⁴ and R⁵ are each independently -H;

Q is -C(O)OR; and


R is -H or C₁₋₄ alkyl,

provided that the compound of Formula (IV) is not compound no. 2



, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound of Formula (IV) is a compound of Formula (V)









or a pharmaceutically acceptable salt thereof.

3. The compound of either of claims 1 or 2, wherein X^1 is $-F$ or $-Cl$.
4. The compound of any one of claims 1-3, wherein X^2 is $-F$ or $-Cl$.
5. The compound of any one of claims 1-4, wherein Z^1 is CH .
6. The compound of any one of claims 1-4, wherein Z^1 is N .
7. The compound of any one of claims 1-6, wherein Z^2 is N , $C-F$, or $C-CN$.
8. The compound of any one of claims 1-7, wherein R^1 , R^2 , and R^3 are each independently $-CH_3$ or $-C_2H_5$.
9. The compound of any one of claims 1-8, wherein R is $-H$.
10. The compound of claim 1, wherein the compound of Formula **(IV)** is selected from

1		3

4	5	6
7	9	16
17	18	43
47	48	76

<p>79</p> 	<p>84</p> 	<p>85</p> 
<p>89</p> 	<p>90</p> 	<p>97</p> 

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising a compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.


12. A compound as described in any one of claims 1-10, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for use in inhibiting the replication of influenza viruses in a patient; for use in reducing the amount of influenza viruses in a patient; or for use in treating influenza in a patient.

13. A method of inhibiting the replication of influenza viruses in a biological sample, or reducing the amount of influenza viruses in a biological sample, comprising the step of administering to said biological sample an effective amount of a compound as described in any one of claims 1-10.

14. The method of claim 13, for inhibiting the replication of influenza viruses in a biological sample, further comprising co-administering an additional therapeutic agent; such as wherein the additional therapeutic agent is selected from an antiviral agent or an Influenza vaccine.

15. A compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of influenza virus infection in a patient.

16. A method of preparing a compound of Formula (IV)



or a pharmaceutically acceptable salt thereof, wherein

X¹ is -F, -Cl, -CF₃, -CN, or -CH₃;

X² is -H, -F, or -Cl;

Z¹ is N or CH;

Z² is N or CR⁰;

R⁰ is -H, -F, or -CN;


R¹, R², and R³ are each independently -CH₃, -CH₂F, -CF₃, -C₂H₅, -CH₂CH₂F, or -CH₂CF₃;

R⁴ and R⁵ are each independently -H;

Q is -C(O)OR; and


R is -H or C₁₋₄ alkyl,

provided that the compound of Formula (IV) is not compound no. 2




, or a pharmaceutically acceptable salt thereof, comprising the steps of:

- (i) reacting a compound having the formula
-
- wherein L^2 is a




halogen, with compound **B**, wherein G is trityl, to form a compound



; and

- (ii) deprotecting the G group of the compound synthesized in step (i) under suitable conditions to form a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.

17. A method of preparing a compound of Formula (IV):



or a pharmaceutically acceptable salt thereof, wherein

X¹ is -F, -Cl, -CF₃, -CN, or -CH₃;

X² is -H, -F, or -Cl;

Z¹ is N or CH;

Z² is N or CR⁰;

R⁰ is -H, -F, or -CN;


R¹, R², and R³ are each independently -CH₃, -CH₂F, -CF₃, -C₂H₅, -CH₂CH₂F, or -CH₂CF₃;

R⁴ and R⁵ are each independently -H;

Q is -C(O)OR; and


R is -H or C₁₋₄ alkyl,

provided that the compound of Formula **(IV)** is not compound no. 2





, or a pharmaceutically acceptable salt thereof,

comprising the steps of:



(i) reacting a compound **(K)**

or a compound **(L)**



(ii) deprotecting the G group of the resulting compound under suitable conditions to form a compound of Formula (IV).